New insights emerge when therapeutic innovation and diagnostic innovation work hand in hand.
Through our collaboration with CytoDyn, Signatera™ will be used to evaluate molecular response patterns associated with leronlimab treatment in metastatic colorectal cancer. Natera will also contribute real-world data insights leveraging our proprietary oncology database, which includes more than 2 million plasma timepoints and enriched clinical and imaging data.
We are pleased to partner with CytoDyn as it advances the development of leronlimab. Together, we aim to generate evidence that may help inform drug development and advance our understanding of treatment response. Most importantly, every new insight has the potential to bring us closer to better outcomes for patients. https://t.co/EXiOBw08VJ
$CYDY
Natera and CytoDyn Announce Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer
https://t.co/1vjGrz79C2
#Leronliamb is changing the lives of many patients.
https://t.co/jwybCARq5p
#Oncology
Safety and 5-year survival following treatment with leronlimab plus physician’s choice combination therapy in patients with metastatic triple-negative breast cancer.
https://t.co/FBjjzSr8Rr
https://t.co/jwybCARq5p
#oncology#TNBC#ASCO#Leronliamb#CancerResearch
Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.
https://t.co/jwybCARq5p
https://t.co/3ZpJTFMHah
#oncology#mCRC#leronliamb#colonrectalcancer
$CYDY
This small biotech company changes people's health for the better. It will change people's bank account for the better.
Do your DD on https://t.co/jwybCARq5p
#stocks#stockstowatch#oncology#ccr5#cancer
$CYDY
#Leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab for patients with refractory metastatic colorectal cancer (mCRC): The phase 2 CLOVER study.
https://t.co/nV23mYeyN4
#Oncology#Coloncancer#Breastcancer#HIV
https://t.co/jwybCARq5p
$CYDY
Safety and 5-year survival following treatment with leronlimab plus physician’s choice combination therapy in patients with metastatic triple-negative breast cancer.
https://t.co/FBjjzSr8Rr
#Oncology#Leronliamb#breastcancer#coloncancer
https://t.co/jwybCARq5p
$CYDY
Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease (SALIENT-AD)
https://t.co/dXr5sjKktU
https://t.co/jwybCARq5p
#Alzheimers#CCR5#cancer#HIV
$CYDY
Congrats! Cytodyn is a totally different company since Dr. Jacob Lalezari became CEO in 2024. #Leronliamb is going to continue to help the most sick with tNBC and mCRC not to mention HIV. New studies for liver fibrosis and cognitive disorders.
#CCR5#biotech